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Introduction: Systemic sclerosis (SSc) is an autoimmune disease of the connective tissue char-
acterized by the triad of vascular injury, autoimmunity (cellular and humoral) and tissue
ﬁbrosis. It is estimated that musculoskeletal pain is a common complaint of patients with
SSc, ranging from 40 to 80%, and mainly in patients with early diffuse disease. Arthritis,
clinically observed, may be a feature seen in the presentation of SSc, often leading to early
diagnostic errors with rheumatoid arthritis (RA). In the course of the disease, arthritis is
observed in 24–97% of patients with SSc.
Objectives: To correlate the occurrence or nonoccurrence of arthritis in patients with SSc of
the  Midwest region of Brazil with possible distinct clinical and laboratory manifestations
observed in three groups of patients. To report the frequency of true association between
systemic sclerosis and rheumatoid arthritis in patients with clinically and radiologically
observed synovitis.
Methods: Sixty-one SSc patients were subsequently assessed every 3 months within 1 year,
in  order to clinically observe the occurrence of synovitis and its patterns of progression.
Patients were divided into 3 groups: 41 patients with SSc without arthritis, 16 SSc patients
with arthritis and 4 patients with overlap of SSc and RA. All patients underwent a radiological
examination of the hands at the end of the study.
Results: Among all patients evaluated, we found a female predominance (98.7%), mean age
of  50.94 years, white color (49.2%), limited form of the disease (47.6%), time of diagnosis
between 5 and 10 years (47.6%) and duration of the disease of 8.30 years. Among all patients,
14  (22.9%) had positive rheumatoid factor (RF), while among those with positive RF, only
10  patients had arthritis during one-year follow-up. The antibody anticitrulline (anti-CCP)
test was performed in 24 patients, being positive in 4 of them (16.7%), with positivity being
observed only in patients with SSc/RA overlap. Comparing the clinical manifestations among
the  groups of patients, there was a higher incidence of gastritis and cardiac valvulopathy in
patients with SSc and arthritis, but not in the others. In the group of patients with SSc/RA
overlap and in patients with SSc and arthritis a signiﬁcant reduction in quality of life wasobserved, measured by HAQ index, especially in patients with arthritis present during clin-
ical  evaluation. We  found radiographic changes in 42.6% of patients with SSc. However,
in  patients with synovitis, radiological changes consistent with rheumatoid arthritis were
found in 50% of patients.
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Conclusions: While the frequency of clinical arthritis observed in patients with systemic
sclerosis was 32.8%, the true overlap between of SSc and RA was 6.6% in this study. We
also observed the frequency of positive anti-CCP in 20% of patients with arthritis versus no
patients with SSc without arthritis.
© 2015 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Sobreposic¸ão de  esclerose  sistêmica  e  artrite  reumatoide:  uma  entidade
clínica  distinta?
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Introduc¸ão: A esclerose sistêmica (ES) é uma enfermidade do tecido conjuntivo de caráter
autoimune caracterizada pela tríade de injúria vascular, autoimunidade (celular e humoral)
e  ﬁbrose tecidual. Estima-se que a dor musculoesquelética seja uma queixa frequente dos
pacientes com ES, oscilando entre 40 a 80% e principalmente em pacientes com doenc¸a
difusa precoce. A artrite, clinicamente observada, pode ser uma característica observada
na  apresentac¸ão da ES, frequentemente levando a erros diagnósticos iniciais com artrite
reumatoide (AR). No curso da enfermidade, a artrite é observada em 24 a 97% dos pacientes
com  ES.
Objetivos: Correlacionar a ocorrência ou não de artrite em pacientes com ES da região Centro
Oeste do Brasil com possíveis manifestac¸ões clínicas e laboratoriais distintas observadas
em  três grupos de pacientes. Relatar a frequência de verdadeira associac¸ão entre escle-
rose sistêmica e artrite reumatoide em pacientes com sinovite clínica e radiologicamente
observada.
Métodos: 61 pacientes portadores de ES foram avaliados subsequentemente a cada 3 meses
durante o período de um ano, para ﬁns de se constatar clinicamente a ocorrência de sinovite
e  padrões de evoluc¸ão. Os pacientes foram divididos em 3 grupos: 41 pacientes com ES sem
artrite, 16 pacientes com ES com artrite e 4 pacientes com sobreposic¸ão entre ES e AR. Todos
os  pacientes foram submetidos a exame radiológico das mãos no ﬁnal do estudo.
Resultados: Dentre todos os pacientes avaliados, encontrou-se predomínio feminino (98,7%),
idade média de 50,94 anos, cor branca (49,2%), forma limitada da doenc¸a (47,6%), tempo de
diagnóstico entre 5 a 10 anos (47,6%)e tempo de evoluc¸ão da doenc¸a de 8,30 anos. Entre todos
os  pacientes, 14 (22,9%) apresentavam fator reumatoide (FR) positivo, embora entre aqueles
com FR positivo, apenas 10 pacientes apresentaram artrite durante o seguimento de um
ano.  O anticorpo anticitrulina (anti CCP) foi realizado em 24 pacientes, com positividade em
4  deles (16,7%), sendo a positividade observada somente nos pacientes com sobreposic¸ão
ES/AR. Comparando-se as manifestac¸ões clínicas entre os grupos de pacientes, observou-se
a  maior ocorrência de gastrite e valvulopatia cardíaca em pacientes com ES e artrite, mas
não nos demais grupos. No grupo de pacientes com overlap ES/AR e nos pacientes com ES
e  artrite observou-se reduc¸ão importante de qualidade de vida, medido pelo índice HAQ,
sobretudo nos pacientes com artrite presente no momento da avaliac¸ão clínica. Encon-
tramos alterac¸ões radiográﬁcas em 42,6% dos pacientes com ES. Contudo, nos pacientes
com  sinovite, encontrou-se alterac¸ões radiológicas compatíveis com artrite reumatoide em
50% dos pacientes.
Conclusões: Enquanto a frequência de artrite clínica observada em pacientes com esclerose
sistêmica foi de 32,8%, a verdadeira sobreposic¸ão entre ES e AR foi de 6,6% neste estudo.
Observou-se ainda a frequência de anti CCP positivo em 20% dos pacientes com artrite
contra nenhum paciente com ES sem artrite.
© 2015 ElseviIntroductionSystemic sclerosis (SSc) is an autoimmune disease of the con-
nective tissue that is extremely heterogeneous in its clinical
presentation, with involvement of multiple systems, follow-
ing a variable and unpredictable course.1 Its etiology remainser Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CC
BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
unknown, with a multifactorial cause being suggested, pos-
sibly triggered by environmental factors in a genetically
predisposed individual.2
SSc is mainly characterized by microvasculopathy, activa-
tion of ﬁbroblasts and excessive collagen production.3 This
is a unique condition as it has characteristics of three dis-
tinct pathophysiological processes: it consists of the triad of
vascular injury, autoimmunity (cellular and humoral) and
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issue ﬁbrosis, leading to involvement of skin and several
nternal organs like lungs, heart, gastrointestinal tract, as well
s musculoskeletal manifestations.3,4
It is estimated that musculoskeletal (ME) pain is a frequent
omplaint of SSc patients, ranging from 40 to 80% and espe-
ially in patients with early diffuse disease.5 The main ME
ymptoms shown are movement  limitations, joint pain and/or
welling.6 Arthritis, clinically observed, may be a feature in the
nitial presentation of SSc, often leading to initial diagnostic
rrors with rheumatoid arthritis (RA).7,8 In a series of cases
escribed by Rodnan Medsger, Jr., in 41% of patients, arthritis
r polyarthralgia was the ﬁrst symptom, or developed within
he ﬁrst year after the onset of Raynaud’s phenomenon.8 In
he course of the disease, arthritis is observed in 24–97% of
atients with SSc.6
Joint lesions, ranging from periarticular osteopenia and
oint space narrowing to apparent erosions, have been
eported in the metacarpophalangeal, proximal interpha-
angeal and distal interphalangeal joints, as well as in the
rists.5,6 According to Rodnan, the most common radiolog-
cal abnormality seen in the bones and joints of patients with
Sc was the resorption of the terminal phalanges (acroosteoly-
is), which was often followed by subcutaneous calcinosis.8 In
act, after progression greater than 7 years of SSc, bone erosion
as observed, especially in the hands, in 4–57% of patients,
hile joint space reduction was observed in 16–92% of cases.5
lthough many  radiographic changes have been identiﬁed in
he joints of patients with SSc, important erosive arthropathy
s considered unusual.9
Synovial biopsies of the joints of patients with SSc showed
vidence of varying severity of inﬂammation, and in most
ases, an inﬁltrate of lymphocytes and plasma cells dis-
ributed diffusely in the tissue or collected in small focal
ggregates was observed.8 Unlike the ﬁndings observed in
atients with RA, little or no tendency to the formation of pan-
us and intense synovial ﬁbrosis later in the disease course
as reported in SSc patients.8
There are isolated reports of erosive arthritis affecting
rists and hands, with radiological and serological features
hat are indistinguishable from those observed in RA.10 How-
ver, it is still under discussion whether erosive arthritis is part
f SSc, if it could be a manifestation of an overlap syndrome,
r the manifestation of a different independent disease.11
hether rheumatoid arthritis and systemic sclerosis could
oexist in the same patient has also been subject of much
ontroversy.6 While some studies associate erosive arthritis
ith the presence of rheumatoid factor, suggesting an associ-
tion between the two diseases,7,12 others have not conﬁrmed
hese data.10,11,13
This study was expected to conﬁrm the occurrence of typi-
al clinical and laboratory manifestations in a subgroup of SSc
atients with clinically and radiologically observed arthritis,
s suggested by previous studies.bjectives
o correlate the occurrence or nonoccurrence of arthritis in
Sc patients from the Midwest region of Brazil with possible
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distinct clinical and laboratory manifestations observed in
three groups of patients.
To report the true frequency of association between sys-
temic sclerosis and rheumatoid arthritis in patients with
clinically and radiologically observed synovitis.
Methods
This is an observational, analytical, and cross-sectional study.
The random selection of 61 patients was performed based
on a survey of medical records from the Rheumatology Service
of the University Hospital at the School of Medicine of the
Federal University of Mato Grosso do Sul (FMUFMS).
For comparison, the patients were divided into 3 groups:
- 41 SSc patients without arthritis;
- 16 SSc patients with arthritis;
- 4 patients with overlap of SSc and RA.
The patients to be selected should meet the following crite-
ria:
- Meet the new 2013 classiﬁcation criteria for SSc14;
- In the case of lack of skin thickening, they should meet the
criteria of early SSc by LeRoy and Medsger 200115;
- For the diagnosis of true overlap with rheumatoid arthritis,
the RA classiﬁcation criteria of the 2010 ACR/EULAR were
used,16 and also the mandatory presence of anticitrulline
antibody (anti-CCP) and/or typical radiological manifesta-
tions of the disease;
- Patients who had other associated infectious diseases or
malignancies were excluded.
The information required for sociodemographic and clin-
ical characterization of the disease was obtained from each
patient’s charts of medical records, and they were supple-
mented with patient interviews. In the ﬁrst consultation,
demographic and clinical data were collected, including
disease duration, year of diagnosis, skin score of modi-
ﬁed Rodnan,17 presence of autoantibodies, thorough clinical
examination and current treatment. Patients were subse-
quently assessed every 3 months during the ﬁrst year, to
clinically observe the occurrence of synovitis and its patterns
of progression. All patients underwent a radiological exami-
nation of the hands at the end of the study.
Speciﬁc data on the Medsger’s severity scale,18 Valen-
tini’s activity criteria of the disease19 and the Scleroderma
Health Assessment Questionnaire (sHAQ)20 were collected in
the patient’s initial assessment and also in a second eval-
uation, only in those who presented clinical evidence of
synovitis.
Regarding serum samples, sera from patients previously
selected and which were frozen at −50 ◦C and properly stored
in the Laboratory of the University Hospital of UFMS were used
for the research.. Antinuclear Antibodies (ANA)
Indirect immunoﬂuorescent technique was used for the
analysis of ANA, having HEp2 cells as substrate (Faar
 o l . 2
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technique) and using the criteria of the II Brazilian con-
sensus of antinuclear antibodies in Hep-2 cells (2003),21 for
the interpretation of the results.
Sera were considered positive if the title was greater than
or equal to 160 and diluted until ﬂuorescence became neg-
ative.
b. Anti-Sm, anti-RNP, anti-Jo1, anti-Ro (SSA) and anti-La (SSB)
tests – enzyme immunoassay (ELISA) technique was used
as previously described by McClain,22 using substrate-
speciﬁc kits for each test, following the manufacturer’s
speciﬁcations (Hemagen Diagnostics, Inc.). The test was
considered positive when the value found was 3 times or
more higher than cut-off.
c. Rheumatoid factor research – a technique of nephelometry
was used and it was considered positive if the title was
greater than 40 IU/ml.
. Anti-CCP test – enzyme-linked immunosorbent assay
(ELISA) technique was used, following the manufacturer’s
speciﬁcations (INOVA QUANTA LiteTM CCP3.1 IgG/IgA
ELISA). The test was considered negative if <20 units,
weakly reactive between 20 and 39 units, moderately reac-
tive between 40 and 60 units, and highly reactive (high
values) if >60 units.
e. For the anti-centromere research – indirect immuno-
ﬂuorescence technique was used, having HEp2 cells as
substrate according to the criteria of the II Brazilian con-
sensus of antinuclear antibodies in Hep-2 cells (2003),21 for
the interpretation of results.
f. For anti-DNA topoisomerase 1 (anti-Scl70) test –
immunoassay technique was used,23 using a spe-
ciﬁc kit QUANTA Lite TM Scl-70 from the laboratory
INOVA (INOVA Diagnostics, Inc., San Diego, CA, USA)
following the manufacturer’s speciﬁcations. It was
considered nonreactive if <20 units, weakly reactive
between 20 and 39 units, moderately reactive between
40 and 80 units, and highly reactive (high values) if
>80 units.
g. Anti-RNA polymerase III – ELISA technique was used
as previously described,24 using a speciﬁc kit QUANTA
Lite RNA POL III ELISA from INOVA laboratory (INOVA
Diagnostics, Inc., San Diego, CA, USA) following the
manufacturer’s speciﬁcations. It was considered neg-
ative if values <20 units, weakly reactive if between
20 and 39 units, moderately reactive between 40
and 80 units, and strongly reactive (higher values) if
>80 units.
Statistical  analysis
The comparison between patients with and without arthritis
in relation to the quantitative variables evaluated in this study
was performed using the Student t-test. The chi-square test
was used to examine the association between presence and
absence of arthritis with qualitative variables measured in this
study. The results of the other variables evaluated in this study
were presented in descriptive form or in the form of tables
and graphs. Statistical analysis was performed using the
software SPSS, version 20.0, considering a signiﬁcance level
of 5%. 0 1 6;5 6(4):287–298
Results
A total of 61 patients, with 60 (98.7%) being women and 1 (1.6%)
a man, with a mean age of 50.94 ± 2.40 years (mean ± standard
error of the mean), was found.
Of all patients, 30 (49.2%) patients were reported to be
white, 28 (45.9%) patients were reported having brown color
and 3 (4.9%) were reported being black.
Regarding the diagnosis, 58 (95.1%) patients diagnosed met
the criteria for classiﬁcation of 2013 ACR/EULAR for SSc. The 3
(4.9%) patients who did not meet these criteria, met  the criteria
by Leroy/Medsger for early SSc.
Regarding the clinical forms of the disease, 29 (47.6%)
patients had the limited form, 20 (32.8%) patients had the
diffuse form, 3 (4.9%) patients had the early form, 8 (13.1%)
patients had the overlap form (1.6%) and 1 patient had the
form sine scleroderma.
Regarding the time for diagnosis, 16 (26.2%) patients were
diagnosed more  than 10 years before, 29 (47.6%) patients were
diagnosed between 5 and 10 years before, and 16 (26.2%)
patients were diagnosed less than 5 years before. The pro-
gression of the disease in patients in general was 8.30 ± 1.01
years.
Among all patients, 14 (22.9%) were positive for rheuma-
toid factor. The positivity of rheumatoid factor was 9.8% in
patients with SSc without arthritis, 37.5% in the SSc group
with arthritis, and 100% in the group with SSc/RA over-
lap. The anticitrulline antibody (anti-CCP) was performed
in 24 patients, being positive in 4 (16.7%) of these, with
positivity being observed only in patients with SSc/RA asso-
ciation. Among patients with true SSc/RA overlap, half was
of limited form (n = 2–50.0%), one patient was of diffuse form
(n = 1–25.0%) and one patient had association with Sjögren
syndrome (n = 1–25.0%).
The results regarding the epidemiological data and the
monitoring index in SSc patients without arthritis, SSc with
arthritis, and overlap SSc/RA are shown in Table 1. There was
no signiﬁcant difference between patients with SSc without
arthritis, SSc with arthritis and SSc/RA overlap in relation
to the quantitative variables age, time of Raynaud’s phe-
nomenon (RP) before diagnosis, disease duration not counting
RP and monitoring indices (one-way ANOVA, p values ran-
ging between 0.046 and 0.872; HQ2: Student’s t-test, p = 0.071).
Likewise, there was no association between the different
experimental groups and the nominal or ordinal qualitative
variables gender, color, time of diagnosis and clinical form
(chi-square test, p value ranging from .758 to .941).
Table 2 shows the distribution of the patients evaluated
in this study and results regarding skin, vascular and muscu-
loskeletal disorders, in SSc patients without arthritis, SSc with
arthritis, and overlap of SSc/RA. Overall, there was no asso-
ciation between the experimental groups and the variables
related to skin, vascular and musculoskeletal manifestations
observed in the patients evaluated in this study (chi-square
test, p values ranging from 0.145 to 0.630). There was also
no difference between patients with and without arthritis in
relation to skin score (One-way ANOVA test, p = 0.513).
Except for gastritis (p = 0.016) and valvar heart disease
(p = 0.014), in which SSc patients with arthritis (gastritis:
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Table 1 – Demographic aspects and monitoring indexes in patients with SSc without arthritis, SSc with arthritis and
SSc/RA overlap.
Variable Group p value
SSc without arthritis SSc with arthritis SSc/RA overlap
Epidemiological data
Age 50.83 ± 1.96 50.31 ± 3.04 54.00 ± 8.18 0.872
Gender
Male 1 (2.4) 0 (0.0) 0 (0.0) 0.780
Female 40 (97.6) 16 (100.0) 4 (100.0)
Color
White 20 (48.8) 9 (56.2) 1 (25.0) 0.758
Brown 19 (46.3) 6 (37.5) 3 (75.0)
Black 2 (4.9) 1 (6.2) 0 (0.0)
Time of diagnosis
Less than 5 years 11 (26.8) 4 (26.7) 1 (25.0) 0.595
Between 5 and 10 years 17 (41.5) 8 (53.3) 3 (75.0)
More than 10 years 13 (31.7) 3 (20.0) 0 (0.0)
Time of RP before diagnosis 2.68 ± 0.84 5.56 ± 2.16 6.50 ± 4.57 0.235
Time of disease without counting RP 9.41 ± 1.05 7.44 ± 1.20 6.25 ± 1.03 0.396
Clinical form
Limited 18 (43.9) 9 (52.6) 2 (50.0) 0.941
Diffuse 14 (34.1) 5 (31.2) 1 (25.0)
Recent onset 3 (7.3) 0 (0.0) 0 (0.0)
Overlap 5 (12.2) 2 (12.5) 1 (25.0)
Sine 1 (2.4) 0 (0.0) 0 (0.0)
Monitoring indexes
sHAQ 1 (n = 61) 0.59 ± 0.07 0.71 ± 0.08 0.97 ± 0.17 0.163
sHAQ 2 (n = 20) – 0.75 ± 0.08a 1.09 ± 0.14a 0.071a
Severity scale 5.29 ± 0.49 4.00 ± 0.53 4.50 ± 1.04 0.300
Activity scale 2.29 ± 0.21 2.50 ± 0.34 2.50 ± 0.68 0.854
SSc: systemic sclerosis, RA: rheumatoid arthritis, RP: Raynaud’s phenomenon, sHAQ: Scleroderma Health Assessment Questionnaire.
The results are presented in median ± standard error of the median or absolute frequency (relative frequency). p value on one-way ANOVA test.
Equal letters on line indicate that there is no signiﬁcant difference among the groups after Tukey’s test.
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 = 7–43.8%, valvar disease: n = 7–100.0%) showed a higher
ercent of cases when compared with those with SSc with-
ut arthritis (gastritis: n = 5–12.2%; valvulopathy: n = 11–26.8%),
here was no association between the experimental groups of
Sc without arthritis, SSc with arthritis and SSc/RA overlap
ith variables related to other gastrointestinal, cardiopul-
onary and renal manifestations observed in the patients
valuated in this study (chi-square test, p values ranging
rom 0.088 to 0.924). There was no signiﬁcant difference
etween the experimental groups in relation to the quan-
itative variable pulmonary functional vital capacity (FVC)
One-way ANOVA test, p = 0.313). Moreover, it was not possi-
le to compare patients with SSc without arthritis, SSc with
rthritis, and SSc/RA overlap, regarding the estimated pul-
onary artery pressure by echocardiography (EcoPSAP) as out
f the 16 SSc patients with arthritis, this measure was only per-
ormed in one patient and was not performed in any patient
ith SSc/RA overlap. These results are shown in Table 3.
The results of the laboratory tests in SSc patients with-ut arthritis, SSc with arthritis and SSc/RA overlap are shown
n Table 4. There was no difference between patients with
nd without arthritis regarding erythrocyte sedimentation
ate, C-reactive protein, creatine phosphokinase, C3 and C4complements (one-way ANOVA, p value ranging from p = 0.467
to p = 0.952). Moreover, in relation to the results of the labora-
tory tests, there was no association between the experimental
groups and the result for anti-Ro, anti-La, anti-Sm, anti-RNP,
anti-Jo 1, anti-Scl 70, anticentromere and anti-RNA Pol 3, nei-
ther with the result regarding general changes in radiography
(X-ray) of hands (chi-square test, value ranging from 0.073 to
0.816). On the other hand, the percentage of patients with
overlapping SSc/RA who had a reduction in the joint space
or subchondral erosions in the hands X-ray, or positive anti-
CCP (n = 4–100.0%) was greater than that of patients with SSc
with and without arthritis (n = 0–0.0%). Furthermore, the per-
centage of patients with SSc with arthritis and SSc/RA overlap
who had positive rheumatoid factor (n = 6–37.5% n = 4–100.0%,
respectively) was signiﬁcantly higher than that of SSc patients
without arthritis, who also showed positive rheumatoid factor
(n = 4–9.8%; chi-square test, p < 0.05). These results are shown
in Fig. 1.
Among the patients with arthritis (n = 20) the most fre-
quently prescribed drugs were methotrexate (n = 9–45.0%),
azathioprine (n = 7–35.0%), prednisone (n = 6–30.0%), chloro-
quine diphosphate (n = 6–30.0%), and leﬂunomide (n =
6–30.0%). These results are shown in Table 5.
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Table 2 – Skin, vascular, and musculoskeletal manifestations, in patients with SSc without arthritis, SSc with arthritis
and SSc/RA overlap.
Variable Group p value
SSc without arthritis SSc with arthritis SSc/RA overlap
Skin manifestations
Calcinosis
Yes 8 (19.5) 2 (12.5) 0 (0.0) 0.535
Hands
With changes 32 (78.0) 15 (93.8) 3 (75.0)
Findings on hands (n = 50)
Edematous phase 10 (31.2) 7 (46.7) 0 (0.0) 0.197
Indurative phase 8 (25.0) 6 (40.0) 1 (33.3)
Atrophic phase 14 (43.8) 2 (13.3) 2 (66.7)
Skin Rodnan’s score 13.66 ± 1.28 11.50 ± 1.76 16.00 ± 4.74 0.513
Vascular manifestations
RP
Objective 28 (68.3) 13 (81.2) 2 (50.0) 0.408
Subjective 13 (31.7) 3 (18.8) 2 (50.0)
Microscars
Yes 12 (29.3) 1 (6.2) 1  (25.0) 0.177
Active ulcers
Yes 5 (12.2) 1 (6.2) 0 (0.0) 0.630
Necrosis or amputation
Yes 6 (14.6) 0 (0.0) 0 (0.0) 0.197
Telangectasias
Yes 26 (63.4) 11 (68.8) 4 (100.0) 0.327
Musculoskeletal manifestations
Flexion contracture
Yes 6 (14.6) 1 (6.2) 1 (25.0) 0.538
Tendon crepitation
Yes 2 (4.9) 0 (0.0) 0 (0.0) 0.604
Muscle weakness
Yes 7 (17.1) 1 (6.2) 0 (0.0) 0.401
Atrophy
Yes 7 (17.1) 0 (0.0) 0 (0.0) 0.145
ome
r absoSSc: systemic sclerosis, RA: rheumatoid arthritis, RP: Raynaud’s phen
The results are presented in median ± standard error of the median o
Discussion
Joint involvement with severe synovitis is relatively uncom-
mon  in patients with systemic sclerosis (SSc).25 About 11% of
SSc patients present with arthritis at the onset of the disease,
usually characterized by mono- or oligoarthritis, responsive to
corticosteroid therapy. However, some patients with SSc have
more aggressive erosive arthritis, mimicking classic rheuma-
toid arthritis (RA).25
A rate of 6.6% of overlap with RA was observed in this
study in 61 patients with SSc and musculoskeletal symptoms
were very prevalent in these patients with or without associ-
ation between the diseases, mainly represented by arthritis
in almost a third of them. Other studies in Brazil found a
higher prevalence of osteoarticular manifestations (47.7%),26
with arthralgia ranging from 70.5% to 84.5%,10,27,28 in addition
to arthritis described in 17.6–44.4% of patients.10,27 However,
the prevalence of true overlap with RA has been described as
6,11,12being of 4.3–5.2% in other studies with patients with SSc.
An important aspect observed in our patients was that the
presence of arthritis contributed a lot to the functional deﬁcit
and lower quality of life measured by sHAQ. With sHAQ, muchnon.
lute frequency (relative frequency). p value on one-way ANOVA test.
higher disability scores were observed in the second clinical
evaluation in patients with arthritis, although a direct compar-
ison with patients without arthritis was not possible. Morita
and colleagues reported that patients with diffuse SSc had the
highest rates of disability in HAQ, higher than those of patients
with RA, SLE and other collagen vascular diseases.29 It was
also observed that patients with SSc and joint involvement
had higher scores in HAQ than patients with psoriatic arthritis,
while the pain domain was higher in SSc patients than in those
with RA.30 An association between HAQ and functional deﬁcit
caused by hands involvement has already been described.31
In addition, it was described that the disability caused by the
involvement of the hands in SSc patients who  did not have
RP at the time of evaluation was as severe as that observed
in a population of patients with RA with comparable disease
duration of 10 years.20 The usefulness of HAQ in the evalu-
ation of patients with SSc was demonstrated by studies that
reported that it can predict the progress and survival in these
patients.32,33 In this work, there was a signiﬁcant positive lin-
ear correlation between sHAQ in patients with arthritis and
disease activity as measured by the Pearson test. Medsger and
colleagues found that the HAQ disability indexes had strong
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Table 3 – Gastrointestinal, cardiopulmonary and renal manifestations, in patients with SSc without arthritis, SSc with
arthritis and SSc/RA overlap.
Variable Group p value
SSc without arthritis SSc with arthritis SSc/RA overlap
Gastrointestinal manifestations
Involvement of esophagus
Yes 30 (73.2) 9 (56.2) 3 (75.0) 0.447
Gastrointestinal symptoms
GERD 9 (22.0) 5 (31.3) 2 (50.0) 0.414
Esophagitis 11 (26.8) 2 (12.5) 1 (25.0) 0.510
Gastritis 5 (12.2)b 7 (43.8)a 0 (0.0)ab 0.016
Esophageal hypotonia 6 (14.6) 1 (6.3) 2 (50.0) 0.088
Esophageal dilation 2 (4.9) 1 (6.3) 0 (0.0) 0.875
Cardiopulmonary manifestations
FVC 81.83 ± 2.32 88.31 ± 3.47 85.00 ± 4.74 0.313
FVC – classiﬁcation
>80% 22 (53.7) 11 (68.8) 3 (75.0) 0.887
Between 70 and 80% 13 (31.7) 4 (25.0) 1 (25.0)
Between 50 and 69% 4 (9.8) 1 (6.2) 0 (0.0)
<50% 2 (4.9) 0 (0.0) 0 (0.0)
Chest TC
Altered 19 (46.3) 9 (56.2) 1 (25.0)
Tomography ﬁndings (n = 29)
Fibrosis 14 (73.7) 5 (55.6) 1 (100.0) 0.496
“Ground glass” pattern 5 (26.3) 4 (44.4) 0 (0.0)
Echo PASP 31.23 ± 3.19 (n = 13) 42.00 (n = 1) – –
Result on echocardiogram
Altered 26 (63.4) 7 (43.8) 1 (25.0)
Findings on echocardiogram (n = 34)
Valvulopathy 11 (26.8)b 7 (100.0)a 0 (0.0)ab 0.014
Concentric LVH 9  (22.0) 0 (0.0) 1 (100.0) 0.189
LV diastolic dysfunction 6 (14.6) 2 (28.6) 0 (0.0) 0.924
Mild or moderate PAH 5 (12.2) 1 (14.3) 0 (0.0) 0.668
Pericarditis 4 (9.8) 2 (28.6) 0 (0.0) 0.665
Renal manifestations
Renal crisis
Yes 1 (2.4) 0 (0.0) 0 (0.0) 0.780
SSc: systemic sclerosis, RA: rheumatoid arthritis, GERD: gastroesophagical reﬂux disease, FVC: pulmonary functional vital capacity, Echo PASP:
estimated pressure on pulmonary artery on echocardiogram, LVH: left ventricular hypertrophy, PAH: pulmonary artery hypertension.
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orrelation with skin thickening, cardiac involvement, digi-
al contractures, tendon crepitation, and renal involvement
n 1000 patients with SSc.18
The objective was to study, in this heterogeneous popu-
ation of patients in the Midwest of Brazil, the correlation
etween the presence of clinical and radiological proven
rthritis and the clinical and laboratory manifestations
bserved in patients with SSc. Patients with arthritis who
ere observed during the study period totaled 32.8% of all
atients, with the majority presenting a pattern of mono-
r oligoarthritis with remission after beginning the standard
reatment for systemic sclerosis. However, of the 20 patients
ith demonstrated arthritis, 6 had a pattern of symmetrical
nd additive polyarthritis affecting large and small joints with
rolonged morning stiffness, requiring the use of leﬂunomide
ith or without the use of methotrexate, among other medica-
ions. Of these 6 patients with persistent arthritis, 4 of them
howed positive cyclic citrullinated antipeptid (anti-CCP), as
ell as joint space narrowing and/or subchondral erosions inlute frequency (relative frequency). p value on one-way ANOVA test.
r Tukey’s test.
the radiographs of hands, leading to the conclusion that there
is clearly an overlap with rheumatoid arthritis, and it was nec-
essary to combine rituximab to the therapeutic regimen of two
patients to better control of composite indices of joint activity.
There are isolated reports of erosive arthritis affecting
wrists and hands, with radiological and serological features
that are indistinguishable from those observed in RA.10 How-
ever, whether erosive arthritis is part of SSc, whether it could
be a manifestation of an overlap syndrome or the mani-
festation of a different independent disease is still under
discussion.11 Whether rheumatoid arthritis and systemic
sclerosis could coexist in the same patient has also been the
subject of much controversy.6 While some studies associate
erosive arthritis with the presence of rheumatoid factor, sug-
gesting an overlap between the two diseases,7,12 others have
10,11,13not conﬁrmed these data. In our patients, although the
presence of rheumatoid factor was related to the occurrence of
arthritis in patients, only anti-CCP was undoubtedly related to
the actual occurrence of overlap between SSc and RA, as well
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Table 4 – Laboratory tests and radiographs of hands of patients with SSc without arthritis, SSc with arthritis and SSc/RA
overlap.
Variable Group p value
SSc without arthritis SSc with arthritis SSc/RA overlap
ESR 28.49 ± 3.10 27.81 ± 6.44 25.00 ± 6.44 0.951
CRP 10.21 ± 2.67 14.34 ± 7.09 11.21 ± 6.28 0.792
CPK 130.24 ± 17.99 124.25 ± 18.13 68.25 ± 10.09 0.518
Creatinine 0.77 ± 0.04 0.70 ± 0.03 0.79 ± 0.03 0.467
C3 129.90 ± 4.52 127.50 ± 5.17 128.75 ± 2.87 0.952
C4 32.56 ± 1.76 31.19 ± 2.01 33.25 ± 1.89 0.884
Anti-Ro
Positive 4 (9.8) 3 (18.8) 0 (0.0) 0.479
Anti-La
Positive 0 (0.0) 1 (6.2) 0 (0.0) 0.239
Anti-Sm
Positive 0 (0.0) 1 (6.2) 0 (0.0) 0.239
Anti-RNP
Positive 7 (17.1) 2 (12.5) 1 (25.0) 0.816
Anti-Jo 1
Positive 2 (4.9) 0 (0.0) 0 (0.0) 0.604
Hands X-ray
Altered 18 (43.9) 6 (37.5) 4 (100.0)
Findings on hands X-ray (n = 26)
Calcinosis 6 (33.3) 3 (50.0) 0 (0.0) 0.249
Phalanges reabsorption 12 (66.7) 3 (50.0) 2 (50.0) 0.688
Space reduction/subchondral erosions 0 (0.0)b 0 (0.0)b 4 (100.0)a <0.001
Anti-SCL 70
Positive 10 (24.4) 5 (31.2) 2 (50.0) 0.519
Anti-centromere
Positive 16 (39.0) 8 (50.0) 2 (50.0) 0.718
Anti-RNA Pol 3
Positive 7 (17.1) 0 (0.0) 0 (0.0) 0.145
Rheumatoid factor
Positive 4 (9.8)b 6 (37.5)a 4 (100.0)a <0.001
Anti-CCP (n = 4) (n  = 16) (n  = 4)
Positive 0 (0.0)b 0 (0.0)b 4 (100.0)a <0.001
SSc: systemic sclerosis, RA: rheumatoid arthritis, ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; CPK: creatine phosphokinase;
C3: C3 complement fraction; C4: C4 complement fraction; X-ray: radiograph.
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as the ﬁnding of reduction of the joint space and subchondral
erosions on radiographs of the hands of these patients.
The prevalence of an association between SSc/RA varies
from 4.3 to 5.2% among patients with systemic sclerosis.6,11,12
In addition, a higher incidence of RA in patients with SSc than
in the general population was found.34 It was suggested that
this SSc/RA overlap is a distinct entity according to the dif-
ferent genetic background of patients: signiﬁcantly increased
frequencies of HLA-DR3 and HLA-DR11 were observed in
SSc/RA compared with RA patients and healthy individuals;
also, allele frequencies of HLA-DR1 and HLA-DR4 (shared epi-
topes) were signiﬁcantly higher in SSc/RA and RA than in
12patients with SSc or controls. However, the results obtained
in a large cohort of European Caucasian patients with SSc did
not support the involvement of genes (CCL21, CD244, CDK6)
recently identiﬁed as of susceptibility to RA in these patients.13lute frequency (relative frequency). p value on one-way ANOVA test.
r Tukey’s test.
Anyway, the genetic link is the best explanation for the
occurrence of SSc/RA overlap.35 Several studies have shown
that autoimmune diseases are grouped in families of patients
with SSc.36–39 In a population with 719 patients with SSc,
RA was the second most prevalent disease in a study of
polyautoimmunity (21%) and the most commonly observed
in familial autoimmunity (18%).34 This supports the concept
that these diseases can arise in a shared genetic basis under-
lying various autoimmune phenotypes, with overlap between
SSc/RA being only one of these phenotypes.
Szücs et al. described, in patients with overlap between
SSc/RA, a combination of characteristic clinical manifesta-
tions, both for SSc and RA, with erosive polyarthritis in
82%, pulmonary ﬁbrosis in 77%, esophageal involvement in
55%, and cardiovascular manifestations, while kidney involve-
ment occurred in 23% of patients.12 A single clinical and
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Fig. 1 – Graph showing the percentage of patients with
rheumatoid factor or positive or negative anti-CCP
antibody, among SSc patients without arthritis, SSc with
arthritis, and overlapping SSc/RA. Each column represents
the percentage of patients. a Signiﬁcant difference in
relation to SSc patients without arthritis (chi-square test,
p < 0.001). b Signiﬁcant difference in relation to SSc patients
without arthritis and SSc with arthritis (chi-square test,
p < 0.001). SSc: systemic sclerosis, RA: rheumatoid arthritis.
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perological pattern was also reported, since most patients with
verlap were those of limited form, with positivity of anti-
opoisomerase in 23% of patients but positive anti-centromere
n only 9%.12 However, in this study we found in patients with
Sc/RA overlap an equal proportion of patients with limited
nd diffuse forms, and 50% of positivity of the topoisomerase
nd the anticentromere. Moreover, when comparing the clini-
al manifestations of patients of the group with arthritis, even
he SSc/RA overlap subgroup, to the group of SSc patients with-
ut arthritis, we  could not conﬁrm that the SSc/RA overlap is
n entity clinically distinct from mere  association of SSc and
A.The presence of rheumatoid factor (RF) has been observed
n up to 25% of patients with SSc,6 in agreement with the
resent study, which found a positivity rate of RF of 22.9%
Table 5 – Most frequently used drugs in patients with
arthritis.
Drugs (among patients with arthritis – n = 20) (n) %
Non-steroidal anti-inﬂammatories 13 (65.0)
Methotrexate 9 (45.0)
Azathioprine 7 (35.0)
Prednisone 6 (30.0)
Chloroquine diphosphate 6 (30.0)
Leﬂunomide 6 (30.0)
Rituximab 2 (10.0)
The results are presented in absolute frequency (relative frequency). 6;5 6(4):287–298 295
among 61 patients. In our case, the presence of arthritis cor-
related signiﬁcantly with FR positivity. Misra et al. found RF
positivity in 80% of patients with degenerative arthritis com-
pared with 13% positivity in other patients with SSc.6 We
found positive FR in 50% of patients with arthritis and in 100%
of patients with degenerative arthritis related to radiographic
changes, against 9.8% of patients with SSc without arthritis.
In the latter group of patients, rheumatoid factor was prob-
ably related to the overlap syndrome, since the 4 patients in
this group with positive RF had an association with Sjögren’s
syndrome.
Recently, through the availability of the cyclic citrullinated
antipeptide tests (anti-CCP), the percentage of association
with positive anti-CCP RA has been reported in 1–15% of
patients with SSc.5 A statistically signiﬁcant correlation
between the anti-CCP positivity and the presence of arthri-
tis with marginal erosions in patients with SSc is described,
which could aid in the diagnosis of overlap of SSc and RA, and
enable appropriate treatment.9 However, anti-CCP antibodies
by themselves do not deﬁne rheumatoid arthritis, since the
frequency of positivity of these antibodies in patients with
SSc without arthritis is not known.5 We found anti-CCP posi-
tivity in 20% of SSc patients with arthritis and present in 100%
of patients with degenerative arthritis related to radiographic
changes, versus no SSc patients without arthritis.
Radiographic changes were found in 42.6% of the SSc
patients, particularly characterized by resorption of the dis-
tal phalanges (65.4%) and calcinosis (34.6%) in both groups
with and without arthritis. However, in patients with synovitis
presenting changes on radiographs of the hands, radiological
changes compatible with rheumatoid arthritis were observed
in 50% of these patients, characterized by joint space narrow-
ing and/or subchondral erosions. These RA-like changes were
only found in 4 patients with diagnosis of SSc/RA overlap.
However, both in patients with SSc and arthritis or patients
with SSc/RA overlap, the presence of resorption of the distal
phalanges and calcinosis was seen, but these pathognomonic
changes of SSc were observed less commonly in the second
group. Meanwhile, Allali et al. found radiographic changes
in 80% of 46 patients with SSc who had arthritis, including
joint space narrowing in 37% and erosions in 43% of these
patients.9 The same researcher found that the most common
sites of occurrence of erosions were the proximal interpha-
langeal and radiocarpal joints.9 In a cohort of 58 patients
with SSc, Schmeiser et al. found signs of arthritis in 31%
of patients, with 19% being clinical and 26% radiological.
In a meta-analysis of seven studies, we found a prevalence
of 26% of radiologically detectable arthritis in patients with
SSc.11
The higher incidence of gastritis and cardiac valvulopathy
observed only in patients with SSc and arthritis, but not in the
other groups, can be explained by the more  sustained use, and
in greater amounts, of non-steroid anti-inﬂammatory drugs
(NSAIDs) for joint pain. The group of patients with SSc/RA
overlap, despite a persistent arthritis, promptly began tak-
ing disease-modifying anti-rheumatic drugs (DMARDs) rather
than using NSAIDs. The blockade of cyclooxygenase caused
by the use of NSAIDs reduces the production of inﬂamma-
tory prostaglandins, altering the balance of vasoconstrictor
and dilator factors, contributing to water retention and high
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blood pressure, leading to decompensation of heart failure and
valvulopathies.40,41 Study patients with SSc and arthritis had
a higher association with systemic hypertension (unpublished
data) and the two study patients with SSc and arthritis, who
had valvulopathies, showed no association with rheumatic
fever, systemic lupus erythematosus or antiphospholipid syn-
drome.
Regarding the use of DMARDs, the literature is scarce about
the use of leﬂunomide (LFD) in systemic sclerosis. Sebastiani
et al. observed that LFD was able to improve arthritis related
to SSc in 3 patients. Moreover, organ involvement remained
stable in 2 cases, while skin sclerosis improved in the other
patient.25
The efﬁcacy of rituximab (RTX) as a modifying drug
in patients with rheumatoid arthritis is well documented.
In patients with SSc its use appears to be safe and well
tolerated.42–44 A controlled study prior to RTX indicated that
it can improve lung function in patients with SSc,42 and
a skin improvement was described with the use of mod-
iﬁed Rodnan score42–44 or histological methods,42,44 which
could suggest a potential role of disease-modiﬁcation in the
pathophysiological process of ﬁbrosis in SSc by B lympho-
cyte depletion. In RA, the effective clinical response was not
necessarily correlated with the degree of B-cell inﬁltration in
synovial tissues before treatment.43 But since the local inﬁl-
tration of B cells is an important component of the mode
of action of RTX, Lafyatis et al. highlight that this therapy
may be more  effective when the target tissues show inﬁl-
trates full of B cells, such as pulmonary ﬁbrosis associated with
SSc.43
Biological blockers of tumor necrosis factor (anti-TNF) were
not used in our patients, although they proved to be use-
ful and effective in the treatment of arthritis associated with
inﬂammatory SSc.45–48 Bosello et al. suggested that the use of
anti-TNF in medium-term could also be beneﬁcial to reduce
the progression of ﬁbrotic disease and control of ulcerations,46
but other studies did not observe any improvement in the skin
score and in the pulmonary function with therapy.45,47 More-
over, Omair et al. reported malignancies (breast cancer, basal
cell carcinoma and leukemia) in a third of patients receiving
anti-TNF therapy47 and now the European group of experts
on the scleroderma and systemic sclerosis trials and research
(EUSTAR) does not recommend the routine use.48
Regarding the use of other biologicals in SSc, they were
not necessary in our patients with arthritis due to a good
response with the use of rituximab, although the EUSTAR
group concluded in an observational study that tocilizumab
and abatacept appeared to be safe and effective in the treat-
ment of refractory polyarthritis in patients with SSc, but there
were no signiﬁcant changes in lung or skin ﬁbrosis in both
groups.49
The weakness of the study was the heterogeneity of the
study population, patients with long clinical staging of the
disease, and also the small number of patients in the SSc/RA
overlap group. The relevance of this study is that it described,
for the ﬁrst time in the country, the clinical laboratory fea-
tures of this overlap in patients with SSc. Moreover, this study
conﬁrms the important role of radiographs of the hands, of
rheumatoid factor, and anti-CCP in the evaluation of arthri-
tis in patients with SSc, and it is possible to correlate the
1 0 1 6;5 6(4):287–298
positivity of both antibodies with the occurrence of associ-
ation between SSc and RA.
Conclusions
While the frequency of clinical arthritis observed in patients
with scleroderma was 32.8%, the true overlap between sys-
temic sclerosis and rheumatoid arthritis was 6.6% in this
study.
Except for a higher incidence of gastritis and heart valve
disease, there were no distinct clinical manifestations in
patients with SSc and presence of arthritis compared with a
group of patients without arthritis.
However, the percentage of patients with arthritis who  had
radiographic changes, and positive rheumatoid factor, was
signiﬁcantly higher than those of the SSc patients without
arthritis. We also observed the frequency of positive anti-CCP
in 20% of patients with arthritis versus no patients with SSc
without arthritis.
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